The Study
Myostatin inhibition with orally administered Lactobacillus casei expressing a modified human myostatin protein: functional benefits and translational potential in advanced Duchenne muscular dystrophy
This study gave a special bacteria to old mice with a muscle disease and saw that they could run a little longer on a spinning rod. But it didn't prove the bacteria caused the improvement—maybe something else did. We can't say it would work the same way in people.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Scientists gave mice with advanced muscular dystrophy a special probiotic that tricks the body into making antibodies against a muscle-limiting protein called myostatin.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 520 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The mice moved better, but their muscles didn't rebuild — so the probiotic helps them use what's left better, not fix the damage.
- 2Mice made more anti-myostatin antibodies, had less muscle damage (lower CK at 8 weeks), and could run longer on a spinning rod at 10 rpm after 12 weeks — but their muscles didn't get bigger or less scarred.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Frontiers in Neurology
Year
2026
Authors
Jiwon Lee, Ju-Ah Kim, Yena Oh, K. Kim, Jeehun Lee
Related Content
Claims (6)
When the inactive form of myostatin is blocked, it cannot become active, and muscle growth is not suppressed.
In 32-week-old male mdx mice with advanced Duchenne muscular dystrophy, oral treatment with Lactobacillus casei expressing a modified human myostatin protein increases anti-myostatin antibodies and lowers serum creatine kinase levels, but does not change muscle fiber size or fibrosis.
In aged mice with a severe form of muscular dystrophy, a 12-week course of oral BLS-M22 was linked to better performance on a rotating rod test at 10 rpm, without altering muscle fiber size or scar tissue levels.
In aged mice with a severe form of muscular dystrophy, taking BLS-M22 by mouth does not lead to larger muscle fibers or less scar tissue in the muscles.
In aged mdx mice with advanced Duchenne muscular dystrophy, oral BLS-M22 treatment does not change body weight, even though other measures such as immune activity and physical function show improvement.
In aged mice with a severe form of muscular dystrophy, a treatment called BLS-M22 reduces a marker of muscle damage at 8 weeks but not at 12 weeks, meaning the protective effect does not last.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.